codexis.com - Multiplikator Forward P/S CDXS
Codexis, Inc. (CDXS) relies on moderately stable cash flows from contract work and licenses. Synergy with global pharma behemoths via CodeEvolver accelerates the creation of unique enzymes, while a mature product portfolio optimizes drug synthesis. The forward P/S trend visualizes market revenue expectations, where 1.40 serves as the current metric level, capturing the balance between capitalization and future earnings.
codexis.com - rincian analitis lan metrik utama (CDXS)
- rega pasar lan target rega analis:
- rincian nilai pasar emiten:
- statistik nilai buku emiten:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal Codexis, Inc.|CDXS - Rasio utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Codexis|CDXS - Utang agregat perusahaan|Rasio utang marang kapitalisasi buku CDXS|CDXS - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Codexis, Inc.|Likuiditas cepet codexis.com
- indikator pendapatan resik lan kelipatan nilai:
CDXS - Bathi perusahaan|Proyeksi bathi mangsa ngarep Codexis, Inc.|CDXS - Pangali P/E|Pangali Forward P/E Codexis|CDXS - Pangali rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan CDXS|CDXS - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Codexis, Inc.|CDXS - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan codexis.com|CDXS - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Codexis, Inc.
- indikator volume dodolan lan pendapatan:
Pambiji fundamental perusahaan:CDXS (Codexis Bio)
High switching costs for Codexis, Inc. (CDXS) customers, driven by patent protection of DNA technologies, justify the market's premium revenue expectations. Analyzing the forward price-to-sales ratio, an investor assesses current capitalization by discounting future flows at the WACC rate, where extreme values on the chart signal either an overpayment for the asset or a deep discount in the event of business model degradation.
Analisis perusahaan pesaing
Rasio rega marang prakiraan pendapatan Tempus AI, Inc. TEM|QGEN: Kapitalisasi marang prakiraan pendapatan|Ionis Pharma - Multiplikator Forward P/S|Repligen Inc. (RGEN) - Multiplikator forward rega marang pendapatan|RNA (Avidity Biosciences) - Multiplikator forward rega marang pendapatan|CRSP - Rasio kapitalisasi marang dodolan sing dikarepake|WGS (GeneDx) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Ultragenyx Pharmaceutical Inc. (RARE)|Multiplikator Forward P/S BEAM|Sarepta Corp - Kapitalisasi marang prakiraan pendapatan|Twist Bioscience - Multiplikator forward rega marang pendapatan|TXG: Kapitalisasi marang prakiraan pendapatan|NTLA - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Stoke Therapeutics Inc STOK|BLFS: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan WVE|Rasio rega marang prakiraan pendapatan Maze Therapeutics Inc|Kapitalisasi marang prakiraan pendapatan SION (sionnatx.com)|Multiplikator Forward P/S PRME|Multiplikator Forward P/S Taysha Gene Therapies Inc (TSHA)|Multiplikator Forward P/S QURE (uniQure Corp)|MGTX - Multiplikator forward rega marang pendapatan|RGNX - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep solidbio.com|OCGN: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan PACB|BNTC (Benitec) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Design Corp DSGN|Multiplikator forward rega marang pendapatan RCKT (Rocket Pharmaceuticals)|4dmoleculartherapeutics.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S LXEO (Lexeo Therapeutics, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Korro Bio Inc. (KRRO)|EDIT - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Silence Therapeutics Corp SLN|PRQR (proqr.com) - Multiplikator forward rega marang pendapatan|sangamo.com - Rega forward marang dodolan|NAUT (Nautilus Biotechnology, Inc.) - Multiplikator Forward P/S|Metagenomi Inc. (MGX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Precision BioSciences, Inc. (DTIL)|generationbio.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S BOLD (Boundless Bio, Inc.)|XCUR - Multiplikator forward rega marang pendapatan|IMNN: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Phio Pharmaceuticals PHIO|MBIO: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan TransCode Therapeutics, Inc.|BNGO (Bionano Genomics Inc.) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan APDN (adnas.com)|Multiplikator forward rega marang pendapatan BLUE (bluebird bio)|immunoprecise.com - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Omega OMGA|Rasio kapitalisasi marang dodolan sing dikarepake Singular Genomics Corp (OMIC)|Regulus Therapeutics - Multiplikator Forward P/S|SYRS (syros.com) - Kapitalisasi marang prakiraan pendapatan|Telesis Bio (TBIO) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan TCON|UBX (Unity Bio) - Multiplikator Forward P/S
